Drugs / TG6002
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04194034 | Jan 2020 → Feb 2023 | colorectal neoplasm | Transgene | Terminated | No outcome recorded |
| Phase 1/2 | NCT03724071 | Oct 2018 → Feb 2023 | colorectal neoplasm | Transgene | Terminated | No outcome recorded |
| Phase 1/2 | NCT03294486 | Oct 2017 → May 2019 | brain cancer, glioblastoma | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2022-09-12 | Transgene | Results Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022 transgene.com ↗
TG6002 is able to reach the tumor, replicate, and express its payload after IV administration. |
| 2021-09-16 | Transgene | Results Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002 transgene.com ↗
Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002 |
| 2021-04-09 | Transgene | Results Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses transgene.com ↗ |
| 2020-11-05 | Transgene | Results Transgene reports business update and end Q3 2020 financial position transgene.com ↗ |
| 2020-09-16 | Transgene | Results Positive clinical results for TG4001 and TG6002 and financial visibility secured until 2022 transgene.com ↗
These promising results confirm the safety of TG6002 when given intravenously and are highly supportive of the new generations of oncolytic viruses that we are developing based on our exciting Invir.IO™ platform. |
| 2020-09-08 | Transgene | Results Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002 transgene.com ↗
The first translational data show that, when administered intravenously, TG6002 circulates transiently in the patient’s bloodstream and induces the production of 5 -FU at therapeutic doses. |
| 2019-07-18 | Transgene | Regulatory Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastases transgene.com ↗
Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastases |
| 2019-06-05 | Transgene | Results Peer-reviewed publications confirm the potential of Transgene’s TG4001 and TG6002 transgene.com ↗
Oncolytic virus TG6002 shows increased tumor selectivity and strong antitumor activity in several preclinical models |
All press releases naming this drug 10 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TG6002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03294486 ↗ |
| Known as | VV TK-RR-FCU1 | “Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.” NCT03724071 ↗ |
| Route | Intravenous | “TG6002, administered as 3 weekly IV infusions” NCT03294486 ↗ |